Recommendations for the Treatment of Invasive Fungal Infections in Hematological Malignancies: A Critical Review of Evidence and Turkish Expert Opinion (TEO-1)

The introduction of novel antifungal agents for the treatment of invasive fungal disease in hematological malignancies and also changing treatment strategies have had a great impact in managing affected patients. The medical literature includes some important clinical studies that are being used as evidence for guidelines. The problem with these studies and the guidelines is that they are not very easy to interpret, they include controversial issues, and they are not easy to apply to every patient or country. This paper was designed to critically show the main problems associated with these approaches and provide important information that will help Turkish doctors to adopt them in daily clinical practice.

[1]  J. Cisneros,et al.  Universal antifungal therapy is not needed in persistent febrile neutropenia: a tailored diagnostic and therapeutic approach , 2012, Haematologica.

[2]  R. Haupt,et al.  Empirical versus pre-emptive antifungal therapy for persistent febrile neutropenia , 2012, Haematologica.

[3]  S. Weiler,et al.  Treatment of invasive fungal infections , 2011 .

[4]  L. Pagano,et al.  The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project , 2011, Haematologica.

[5]  F. Gherlinzoni,et al.  What does preemptive antifungal treatment really mean? , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  W. Leisenring,et al.  Empirical versus preemptive antifungal therapy for fever during neutropenia. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  B. D. de Pauw,et al.  Timely intervention for invasive fungal disease: should the road now lead to the laboratory instead of the pharmacy? , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  A. Vekhoff,et al.  Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  R. Foà,et al.  Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G. Petrikkos,et al.  Recent advances in antifungal chemotherapy. , 2007, International journal of antimicrobial agents.

[11]  G. Verhoef,et al.  Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  B. D. Pauw,et al.  Editorial Commentary: Between Over- and Undertreatment of Invasive Fungal Disease , 2005 .

[13]  D. Kontoyiannis,et al.  Caspofungin versus liposomal amphotericin B for empirical therapy. , 2005, The New England journal of medicine.

[14]  F. Marty,et al.  Caspofungin versus liposomal amphotericin B for empirical therapy. , 2005, The New England journal of medicine.

[15]  A. Imhof,et al.  Caspofungin versus liposomal amphotericin B for empirical therapy. , 2005, The New England journal of medicine.

[16]  P. Danaher.  Caspofungin versus liposomal amphotericin B for empirical therapy. , 2005, The New England journal of medicine.

[17]  Thomas J Walsh,et al.  Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. , 2004, The New England journal of medicine.

[18]  Richard Sylvester,et al.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.

[19]  J. Powers,et al.  Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever. , 2002, The New England journal of medicine.

[20]  E. Anaissie,et al.  Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. , 2002, The New England journal of medicine.

[21]  K. Marr.  Empirical antifungal therapy--new options, new tradeoffs. , 2002, The New England journal of medicine.

[22]  E. Anaissie,et al.  A Randomized, Double-Blind Comparative Trial Evaluating the Safety of Liposomal Amphotericin B versus Amphotericin B Lipid Complex in the Empirical Treatment of Febrile Neutropenia , 2000 .

[23]  G. Noel,et al.  Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. , 1999, The Journal of pediatrics.

[24]  R. Finberg,et al.  Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia , 1999 .

[25]  W. Wilson,et al.  Safety, Tolerance, and Pharmacokinetics of a Small Unilamellar Liposomal Formulation of Amphotericin B (AmBisome) in Neutropenic Patients , 1998, Antimicrobial Agents and Chemotherapy.

[26]  J. Wingard,et al.  Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  Warnock Dw.  Treatment of invasive fungal infections. , 1998, Hospital medicine.

[28]  C. R. Pinkerton,et al.  A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients , 1997, British journal of haematology.

[29]  S. Zinner.  Antimicrobial therapy in cancer patients: Studies from the EORTC international antimicrobial therapy cooperative group , 1997 .

[30]  D. Denning,et al.  Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data. , 1995, Archives of internal medicine.

[31]  D. Linch,et al.  Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single‐centre experience of 133 episodes in 116 patients , 1994, British journal of haematology.

[32]  J. Shelhamer,et al.  Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection. , 1994, The Journal of infectious diseases.

[33]  L. Vázquez.  Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever , 2016 .

[34]  B. D. de Pauw.  Between over- and undertreatment of invasive fungal disease. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  P. Cagnoni.  Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. , 2002, The Journal of antimicrobial chemotherapy.

[36]  R. Finberg,et al.  Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. , 1999, The New England journal of medicine.

[37]  H. Prentice,et al.  Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. , 1991, The Journal of antimicrobial chemotherapy.

[38]  P. Fenaux,et al.  Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. , 1991, The Journal of antimicrobial chemotherapy.

[39]  Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. , 1989, The American journal of medicine.

[40]  F. Witebsky,et al.  Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. , 1982, The American journal of medicine.